Dexamethasone, BMP-2, and 1,25-dihydroxyvitamin D enhance a more differentiated osteoblast phenotype: validation of an in vitro model for human bone marrow-derived primary osteoblasts

被引:139
作者
Jorgensen, NR
Henriksen, Z
Sorensen, OH
Civitelli, R
机构
[1] Copenhagen Univ Hosp, Osteoporosis & Bone Metab Unit, DK-2650 Hvidovre, Denmark
[2] Washington Univ, Sch Med, Dept Internal Med, St Louis, MO USA
关键词
osteoblasts; cell differentiation; steroid hormones; glucocorticoids; matrix proteins;
D O I
10.1016/j.steroids.2003.12.005
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In vitro models of bone cells are important for the study of bone biology, including the regulation of bone formation and resorption. In this study, we have validated an in vitro model of human osteoblastic cells obtained from bone marrow biopsies from healthy, young volunteers, aged 20-31 years. Osteoblast phenotypes were induced by either dexamethasone (Dex) or bone morphogenetic protein-2 (BMP-2). Bone marrow was obtained from biopsies at the posterior iliac spine. Cells were isolated by gradient centrifugation and grown to confluence. Cells were treated with 1 nM 1,25-dihydroxyvitamin D (vitamin D), 100 nM Dex, and/or 100 ng/ml BMP-2. The osteoblast phenotype was assessed as alkaline phosphatase (AP) activity/staining, production of osteocalcin and procollagen type 1 (P1NP), parathyroid hormone (PTH)-induced cyclic adenosine mono-phosphate (cAMP) production, and in vitro mineralization. AP activity was increased by Dex, but not by BMP-2 treatment. P1NP production was decreased after Dex treatment, while BMP-2 had no effect on P1NP levels. Osteocalcin production was low in cultures not stimulated with vitamin D. Dex or BMP-2 treatment alone did not affect the basic osteocalcin levels, but in combination with vitamin D, BMP-2 increased the osteocalcin production, while Dex treatment completely suppressed osteocalcin production. Further, PTH-induced cAMP production was greatly enhanced by Dex treatment, whereas BMP-2 did not affect cAMP production. Finally, in vitro mineralization was greatly enhanced in cultures enriched with either BMP-2 or Dex. Cell proliferation was only increased significantly by Dex treatment. In conclusion, the model described produces cells with an osteoblastic phenotype, and both Dex and BMP-2 can be used as osteoblast inducers. However, the two treatments produce osteoblastic cells with different phenotypic characteristics, and a selective activation of some of the most important genes and functions of the mature osteoblast can thus be performed in vitro. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:219 / 226
页数:8
相关论文
共 23 条
[1]   EFFECTS OF 1-ALPHA,25-DIHYDROXYVITAMIN-D3 AND GLUCOCORTICOIDS ON THE GROWTH OF RAT AND MOUSE OSTEOBLAST-LIKE BONE-CELLS [J].
CHEN, TL ;
CONE, CM ;
FELDMAN, D .
CALCIFIED TISSUE INTERNATIONAL, 1983, 35 (06) :806-811
[2]  
CHEN TL, 1986, ENDOCRINOLOGY, V118, P1119, DOI 10.1210/endo-118-3-1119
[3]   DIFFERENTIATION OF HUMAN BONE-MARROW OSTEOGENIC STROMAL CELLS IN VITRO - INDUCTION OF THE OSTEOBLAST PHENOTYPE BY DEXAMETHASONE [J].
CHENG, SL ;
YANG, JW ;
RIFAS, L ;
ZHANG, SF ;
AVIOLI, LV .
ENDOCRINOLOGY, 1994, 134 (01) :277-286
[4]   CHARACTERIZATION OF AN OSTEOBLAST-LIKE CLONAL CELL-LINE WHICH RESPONDS TO BOTH PARATHYROID-HORMONE AND CALCITONIN [J].
FORREST, SM ;
NG, KW ;
FINDLAY, DM ;
MICHELANGELI, VP ;
LIVESEY, SA ;
PARTRIDGE, NC ;
ZAJAC, JD ;
MARTIN, TJ .
CALCIFIED TISSUE INTERNATIONAL, 1985, 37 (01) :51-56
[5]   Differential effects of transforming growth factor beta 2, dexamethasone and 1,25-dihydroxyvitamin D on human bone marrow stromal cells [J].
Fromigue, O ;
Marie, PJ ;
Lomri, A .
CYTOKINE, 1997, 9 (08) :613-623
[6]  
Fromigué O, 1998, J CELL BIOCHEM, V68, P411, DOI 10.1002/(SICI)1097-4644(19980315)68:4<411::AID-JCB2>3.3.CO
[7]  
2-C
[8]   THE EFFECTS OF BONE MORPHOGENETIC PROTEIN-2,PROTEIN-4, AND PROTEIN-6 ON DIFFERENTIATION OF RAT OSTEOBLAST CELLS IN-VITRO [J].
HUGHES, FJ ;
COLLYER, J ;
STANFIELD, M ;
GOODMAN, SA .
ENDOCRINOLOGY, 1995, 136 (06) :2671-2677
[9]  
Ishiyama M., 1995, In Vitro Toxicology, V8, P187
[10]  
KEETING PE, 1991, J BONE MINER RES, V6, P827